Abstract Number: 2370 • 2014 ACR/ARHP Annual Meeting
Management of Perioperative Tumor Necrosis Factor α Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis
Background/Purpose: Tumor Necrosis Factor α inhibitors (TNFi) are widely used in patients with RA (Rheumatoid Arthritis) undergoing orthopedic surgery, yet its optimal perioperative management is…Abstract Number: 1074 • 2014 ACR/ARHP Annual Meeting
A Meta-Analysis of the Risk of Venous Thromboembolism in Inflammatory Rheumatic Diseases
Background/Purpose: We performed a meta-analysis investigating the risk of developing deep vein thrombosis (DVT) and/or pulmonary embolisms (PE) in patients with inflammatory arthritis, vasculitis, and…Abstract Number: 875 • 2014 ACR/ARHP Annual Meeting
Treatment-Related Outcomes in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Pooled Analysis of 12 Randomized Controlled Trials
Background/Purpose: Recent studies have shown that therapies for pulmonary arterial hypertension (PAH) improve exercise capacity, but subgroup analyses suggest that these therapies may be less…Abstract Number: 747 • 2014 ACR/ARHP Annual Meeting
Systemic Sclerosis Patients with Antitopoisomerase Antibodies Showed Significant Association with CCR6 Polymorphisms
Background/Purpose: Systemic sclerosis (SSc), also known as scleroderma, is an inflammatory autoimmune disease characterized by fibrosis of the skin and internal organs, vascular damage and…Abstract Number: 673 • 2014 ACR/ARHP Annual Meeting
A Comparison of Rheumatoid Arthritis and Systemic Lupus Erythematosus Trial Design: Ways to Improve Positive Trials in Systemic Lupus Erythematosus
Background/Purpose: Recent SLE RCTs were examined and compared to rheumatoid arthritis (RA) RCT to suggest modifications to SLE RCTs that could improve the future success…Abstract Number: 477 • 2014 ACR/ARHP Annual Meeting
Leflunomide Use Is Not Associated with an Increased Risk of Lung Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomised Controlled Trials
Background/Purpose Leflunomide is an effective treatment for rheumatoid arthritis. An association between pulmonary adverse events, in particular interstitial lung disease, and leflunomide use has been…Abstract Number: 2772 • 2014 ACR/ARHP Annual Meeting
The Use of Imaging in the Diagnosis of Polymyalgia Rheumatica: Systematic Literature Review and Meta-Analysis
Background/Purpose ACR/EULAR provisional classification criteria for polymyalgia rheumatica (PMR) incorporate musculoskeletal ultrasound of shoulder and hip (bursitis and synovitis given equal weight). Our objective was…Abstract Number: 2537 • 2014 ACR/ARHP Annual Meeting
Diagnostic Accuracies of Sialography and Salivary Ultrasonography in Sjogren’s Syndrome Patients: A Meta-Analysis
Background/Purpose Ultrasonography (US) may come to replace conventional invasive examinations in clinical practice. However, the diagnostic accuracy of salivary US has not been clearly compared…Abstract Number: 2501 • 2014 ACR/ARHP Annual Meeting
Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis
Background/Purpose: Tocilizumab (TCZ) is a recombinant, humanized, monoclonal antibody directed against the cytokine interleukin-6 receptor, and tofacitinib (Tofa) is an oral, synthetic, disease-modifying antirheumatic drug…Abstract Number: 2337 • 2013 ACR/ARHP Annual Meeting
Serious Adverse Events Associated With Using Biological Agents To Treat Rheumatic Diseases: Network Meta-Analysis From a National Guideline Panel
Background/Purpose: Clinical guidelines are needed to help clinicians provide optimal medical treatment and advise patients about the potential hazards associated with certain drugs. Our objective…Abstract Number: 1564 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Influenza Vaccination Is Strongly Decreased In Systemic Lupus Erythematosus: A Meta-Analysis Of Literature Data
Background/Purpose: Several studies suggest that the efficacy of influenza vaccination may be decreased in systemic lupus erythematosus (SLE). We performed a meta-analysis to assess systematically…Abstract Number: 1471 • 2013 ACR/ARHP Annual Meeting
Tofacitinib For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Background/Purpose: Tofacitinib was developed as a small molecule inhibitor of the Janus kinase (JAK) pathways that are central to the maintenance of the inflammatory state…Abstract Number: 745 • 2013 ACR/ARHP Annual Meeting
Rate Of Infection and Development Of Malignancy In Patients With ANCA-Associated Vasculitis Treated With Rituximab: A Meta-Analysis From Randomized Trials
Background/Purpose: Over the past 40 years failures to achieve remission in a proportion of patients and the potential development of significant adverse effects have been…Abstract Number: 498 • 2013 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis Comparing Low- Versus High-Dose Rituximab For Rheumatoid Arthritis
Background/Purpose: The approved dose of rituximab (RTX) for rheumatoid arthritis (RA) is 2x1000 mg infusions given 2 weeks apart. There is contradictory evidence regarding the…Abstract Number: 460 • 2013 ACR/ARHP Annual Meeting
Comparative Efficacy Of Novel Disease-Modifying Antirheumatic Drugs As Monotherapy and In Combination With Methotrexate In Rheumatoid Arthritis Patients With An Inadequate Response To Traditional Disease-Modifying Antirheumatic Drugs: A Network Meta-Analysis
Background/Purpose: To compare ACR responses of novel DMARDs as monotherapy or in combination with methotrexate (MTX), including subcutaneous (SC) abatacept and SC tocilizumab (TCZ), in…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- Next Page »